The need for efficient methods of screening and testing for COVID-19 is at an all-time high as communities have begun to lift their stay-at-home restrictions, and case numbers have started to spike. A team of MUSC researchers is developing a way to test individuals rapidly for immunity against the disease. The researchers hope they will have this technology ready for use in MUSC Health clinics in time for the second wave of COVID-19.
SARS-CoV-2, the virus that causes COVID-19, is covered in sugar molecules called glycans. These glycans can interact with the deep layer of glycans on our own cells and result in viral entry.
MUSC researchers Peggi Angel, Ph.D., Richard Drake, Ph.D., and Anand Mehta, D.Phil., with the Department of Cell and Molecular Pharmacology and Experimental Therapeutics, study sugars attached to proteins. Together, they founded the company GlycoPath, with the goal of generating clinical methods to study changes in glycans associated with various diseases.